Navigation Links
Daiichi Sankyo/Eli Lilly's Effient and Astrazeneca's Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction

Considerable Opportunity Remains for an Antiplatelet Therapy that, Combined with Aspirin, Causes Less Bleeding than the Combination of Plavix/Iscover

and Aspirin, According to a New Report from Decision Resources

WALTHAM, Mass., May 15 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that Daiichi Sankyo/Eli Lilly's Effient offers improvement in patient compared to Sanofi-Aventis/Bristol Myers Squibb's Plavix/Iscover in the treatment of post-myocardial infarction. Effient and AstraZeneca's ticagrelor, which is in Phase III trials, are positioned to offer advantages over Plavix/Iscover such as quick onset of action, greater potency, consistent effect, and a quick offset of action. However, clinical trials demonstrate that Effient cause more major bleeding than Plavix/Iscover and that ticagrelor must be twice-daily dosed, in comparison with Plavix/Iscover's once-daily dose. The new ADP receptor antagonists Effient and ticagrelor will be launched in 2009 and 2011, respectively. However, with Plavix/Iscover's patent expiry in 2011, only modest patient shares are expected for the new agents because of the increased competitiveness of generic clopidogrel.

The new report entitled Post-Myocardial Infarction: Emerging Therapies Must Offer Physicians More Evidence to Prove Clear Benefits further finds that an unmet need exists for an antiplatelet therapy for post-myocardial infarction that is as effective as Plavix/Iscover but that, combined with aspirin, causes less major bleeding than the combination of Plavix/Iscover and aspirin. An agent of this type would earn 43 percent patient share in post-myocardial infarction, according to primary care physicians.

"Surveyed primary care physicians consider less bleeding an important safety attribute, and the results of our survey indicate that they are not satisfied with the level of bleeding caused by the combination of Plavix/Iscover and aspirin," said Jeremy Goldman, M.D., analyst at Decision Resources. "Because Plavix/Iscover is the only adenosine diphosphate receptor antagonist used in combination with aspirin (excluding the occasional use of ticlopidine [Roche/Sanofi-Aventis's Ticlid, Daiichi Sankyo's Panaldine, generics]) in the United States, there is considerable opportunity for an antiplatelet agent that is as effective as Plavix/Iscover when it is added to aspirin but does not bring the higher risk of major bleeding."

About the Report

Post-Myocardial Infarction: Emerging Therapies Must Offer Physicians More Evidence to Prove Clear Benefits is a DecisionBase 2008 report from Decision Resources. DecisionBase 2008 combines market forecasts with clinical and commercial end points to assess market share projections in 35 indications. These outputs are driven by quantitative and qualitative primary research. DecisionBase 2008 provides detailed market share, patient share, and price-per-day projections for emerging drugs in development. The market share projections are based on prescriber surveys that compare physicians' expectations of a potential target product profile with an emerging product profile of the leading drugs in development.

The report can be purchased by contacting Decision Resources. Members of the media may request an interview with an analyst.

About Decision Resources

Decision Resources, Inc. (, is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Elizabeth Marshall

Decision Resources


SOURCE Decision Resources
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. FDA Grants Priority Review for Daiichi Sankyo, Lilly Drug, prasugrel
2. Daiichi Sankyo and Forest Laboratories Finalize Contract for Co-Promotion of AZOR(TM)
3. Results of Phase 3 Study Show Tapentadol IR Relieves Acute Pain and Offers Favorable Gastrointestinal Tolerability Profile
4. New Analysis in Boys and Girls Shows the ADHD Patch, DAYTRANA(TM) (methylphenidate transdermal system), Offered ADHD Symptom Control for 12 Months
5. Divigel(R) (estradiol gel) 0.1 Percent Offers Lowest Approved Dose of Estradiol for Treatment of Moderate to Severe Hot Flashes Associated with Menopause
6. STAR Cranial Centers of Excellence Offer Cutting-Edge Treatment to Dallas Area Children
7. Novel Xeloda(R) Dosing Schedule May Offer Well-Tolerated Alternative for Treatment of Advanced Breast Cancer
8. Clinically Proven Treatment Offers Help to Rosacea Sufferers
9. Arizona Doctor Offers New Addiction Drug Treatment for Meth Addicts Showing More Than 60% Success Rate
10. Biomarkers May Reduce the Need for Biopsies and Offer Personalized Care for Heart and Lung Transplant Patients
11. New York-Presbyterian/Weill Cornell is First New York Medical Center to Offer Tantalus Clinical Trial to Diabetes Patients
Post Your Comments:
(Date:6/26/2016)... DUBLIN , June 27, 2016 Jazz ... the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act ... proposed acquisition of Celator Pharmaceuticals, Inc. ("Celator"; Nasdaq: ... 11:59 p.m. (Eastern Daylight Time). As previously ... entered into a definitive merger agreement under which Jazz ...
(Date:6/24/2016)... 2016  Collagen Matrix, Inc., ("Collagen Matrix") the ... of collagen and mineral based medical devices for ... Bill Messer has joined the company as ... the growing portfolio of oral surgery, neurosurgery, orthopaedic ... joins the Collagen Matrix executive team as an ...
(Date:6/24/2016)... June 24, 2016 Research ... "Structural Electronics 2015-2025: Applications, Technologies, Forecasts" ... In-Mold Electronics, Smart Skin, Structural Health ... Structural electronics involves electronic and/or electrical ... structures, replacing dumb structures such as vehicle bodies ...
Breaking Medicine Technology:
(Date:6/27/2016)... Overland Park, KS (PRWEB) , ... June 27, 2016 , ... ... leader in retailers of Eyeglasses . , Millions of individuals in the United ... life, eyeglasses have become a way to both correct vision and make a fashion ...
(Date:6/26/2016)... ... June 26, 2016 , ... On June 10-11, 2016, A ... 2016 Cereal Festival and World’s Longest Breakfast Table in Battle Creek, MI, where the ... history as home to some of the world’s leading providers of cereal and other ...
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements ... was developed to enhance the health of felines. The formula is all-natural and is ... herbs in the PawPaws Cat Kidney Support Supplement Soft Chews are Astragalus ...
(Date:6/26/2016)... Michigan (PRWEB) , ... June 26, 2016 , ... ... to fertility once they have been diagnosed with endometriosis. These women need a ... they also require a comprehensive approach that can help for preservation of fertility ...
(Date:6/25/2016)... Austin, TX (PRWEB) , ... June 25, 2016 , ... ... Fellow of the American College of Mohs Surgery and to Dr. Russell Peckham for ... popular and highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic ...
Breaking Medicine News(10 mins):